- Home
- RIGL vs ETJ Comparison
RIGL vs ETJ Comparison
Compare RIGL & ETJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | ETJ |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 567.4M |
| IPO Year | 2000 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RIGL | ETJ |
|---|---|---|
| Price | $46.86 | $8.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $45.67 | N/A |
| AVG Volume (30 Days) | ★ 288.3K | 106.4K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.75 | N/A |
| P/E Ratio | $35.21 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $7.88 |
| 52 Week High | $52.24 | $9.12 |
Technical Indicators
Market Signals| Indicator | RIGL | ETJ |
|---|---|---|
| Relative Strength Index (RSI) | 66.46 | 51.87 |
| Support Level | $40.05 | $8.22 |
| Resistance Level | $49.10 | $8.56 |
| Average True Range (ATR) | 1.92 | 0.06 |
| MACD | 0.36 | -0.01 |
| Stochastic Oscillator | 90.87 | 43.75 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.